Drug Topics September 18, 2024
The Eversense 365 is the world’s first long-term CGM that provides 1 year of use and should be available by the fourth quarter of 2024.
The FDA has given clearance to the continuous glucose monitor (CGM) Eversense 365 for adult patients with type 1 and type 2 diabetes, Senseonics and Ascensia Diabetes Care announced in a release.1 Ascensia said that it anticipates a launch of the product to occur in the United States in the fourth quarter of this year.
The Eversense 365 is the world’s first long-term CGM that provides patients with 1 year of use. The fully-implantable device allows for minimal life disruption compared to short-term CGMs, which typically last around 10 to 14 days. The CGMs 12-month...
Today's Sponsors
Today's Sponsor